Endocrine Abstracts

Introduction: In the era of personalized patient management in acromegaly, transsphenoidal surgery remains a treatment of choice in cases where surgical cure can be expected. In order to better target these patients and to assess the risk of persistence/progression disease, we evaluated clinical, hormonal, radiological and pathological predictors of surgical outcome in acromegaly.Methods: A single-institution retrospective study from 2009 to 2015 was per...

Objective: The management of pituitary apoplexy, a rare emergency neuroendocrine condition, is controversial. The aim of the present study was to compare the outcome of patients with pituitary apoplexy managed either by a conservative or surgical approach.Methods: A retrospective cohort study including patients diagnosed between 2007 and 2018 in a tertiary French university hospital. Pituitary apoplexy score was retrospectively applied in a perspective o...

Introduction: 15% of pituitary tumors are considered as aggressive based on resistance to conventional treatment. Less than 40% of these cases respond to temozolomide treatment underlining the need for new therapeutic options. The PI3K/Akt/mTOR pathway, upregulated in different pituitary tumors subtypes, can be targeted by different drugs in particular BKM 120, a pure PI3K inhibitor, and BEZ235, a dual PI3K/mTOR inhibitor.Objective: To study the anti-tum...

Background: Medical treatment of pituitary adenomas with somatostatin analogs depends on tumor type and somatostatin receptor expression. Using polyclonal antibodies, their immunohistochemical (IHC) detection gave conflicting results. Therefore, we studied the IHC expression of SSTR2A and SSTR5 using two specific MABs in five types of pituitary adenomas.Methods: SSTR2A and SSTR5 expression was studied using two...

Objective: Silent corticotroph adenomas (SCA) are rare pituitary tumours immunoreactive for ACTH but without clinical evidence of Cushing’s disease. They have been compared to non functioning pituitary adenomas or ACTH adenomas with Cushing’s disease, but no distinction has been made between micro and macro ACTH-adenomas. We characterize SCA on clinical, hormonal and molecular data and compared the characteristic of these tumours with those of macro (MCA) and micro A...

Introduction: Various tumours have a worse prognosis in male than in female. This is also true for lactotroph tumours. Indeed it is known that aggressive and malignant tumours, resistant to dopamine agonists, are more frequent in male than female and are associated to lower ESR1 expression.Objectives: Our aims are to study the genes differentially expressed and the chromosomic alterations in lactotroph tumours between male and female and their relationsh...

Gonadotroph pituitary tumors (GnPiT) account for ~40% of pituitary tumors surgically treated and 70-75% of non-functional pituitary tumors. Functional gonadotropin-secreting tumors are rare and clinical manifestations vary according to the age and sex of the patient. They are benign tumors which, due to their silent nature, can grow and invade surrounding structures, making complete resection impossible and leading to recurrence in ~30% of cases.Objectiv...

Introduction: Pituitary Neuroendocrine tumours (PitNETs) present heterogenic characteristics based on their hormonal expression and secretion. While most PitNETs have a slow progression rate, a subset of them exhibit an aggressive behaviour with recurrence properties despite current surgery, radio- and chemotherapy. To explore new clinical strategies based on immunotherapy we initiated a systemic cartography of the pituitary tumour immune microenvironment (PiTME).<p class=...

Background: Tumour microenvironment (TME) can comprise >50% of the tumour mass and includes non-tumour cells like immune cells and fibroblasts, as well as extracellular matrix, signaling molecules, and blood and lymph vessels. In recent years, TME has begun to be considered both a prognostic tool and a therapeutic target. While the existence of TME is well accepted and described in numerous cancers, little is known about the TME of pituitary neuroendocrine tumours (PitNETs...

Background: The Phase III PAOLA study assessed the efficacy and safety of pasireotide LAR versus continued treatment with octreotide LAR or lanreotide Autogel in patients with uncontrolled acromegaly. The current analysis investigated overall baseline characteristics and response rates to pasireotide according to co-morbidities.Methods: Patients were classified into five groups of co-morbidities related to acromegaly: glucose- (n=104), endocrine...